Total: $717.04M | ||||
Company |
Type Of |
Number |
Amount |
Investors; Placement |
| | ||||
ALDA |
Private placement of stock and warrants |
2.205S and 2.205W |
C$0.22 (US$0.18) |
Units were sold at C$0.10 each; the 18-month warrants are exercisable at C$0.20 per share; placement agent Canaccord Capital Corp. was paid a 10% fee and received 220,500 warrants (3/16) |
Allos |
Private placement of convertible stock |
N/A |
$52 |
Allos sold the exchangeable preferred stock from a shelf registration to Warburg Pincus Private Equity VIII LP at a 7% discount to a 20-day average; the stock will accrue dividends of 10% if it remains out- standing after 15 months; the total includes a $2M follow-on investment; Needham & Co. Inc. was placement agent (3/3) |
Altachem |
Private placement of convertible notes |
N/A |
C$1 (US$0.82) |
AltaChem issued 8% notes with a one-year maturity that are convertible into common shares at C$0.45 per share (3/23) |
Altachem |
Private placement of stock and warrants |
1.772S and 0.861W |
C$0.44 (US$0.36) |
AltaChem closed the first tranche of the non-brokered placement; the shares sold at C$0.25 each, and the one-year warrants are exercisable at $0.45 per share (3/7) |
Amazon |
Private placement of stock and warrants |
0.7S and 1.1W |
$0.35 |
Amazon closed two deals in which it sold units at $0.50 each; warrants are exercisable at $0.58, $0.72 and $1.13 per share; Parker Financial Corp. got a finder's fee of $25,000 and a warrant to purchase 125,000 shares at $1.13 per share (3/14) |
BioMS Medical |
Private placement of stock and warrants |
11.5S and 11.5W |
C$41.4 (US$34) |
Units consisting of one share and a four-year warrant exercisable at C$5 were sold at C$3.60 each; the underwriting syndicate was led by Fraser Mackenzie Ltd. and included Pacific International Securities Inc. and Dlouhy Merchant Group Inc. (3/23) |
Boston Life |
Private placement of stock |
2S |
$5 |
Shares in the deal were sold at $2.50 each (3/9) |
BrainStorm Cell |
Private placement of securities |
ND |
$1.5 |
The company said it completed the final closing in a $1.5M seed private placement; details were not disclosed (3/1) |
Callisto |
Private placement of stock |
1.99S |
$3.02 |
The shares were sold at $1.52 each in a financing led by current institutional shareholders and including certain members of the company's management (3/10) |
Connetics |
Private placement of convertible notes |
N/A |
$200 |
The 2% notes due in March 2015 are convertible into cash and, under certain circumstances, shares of stock at an initial price of $35.46 per share; the total includes $50M in notes purchased per the lead investor's option (3/17) |
Cytos |
Private placement of stock |
0.46S |
CHF21.4 (US$18.5) |
Swissfirst Bank AG purchased the shares, and placed them with institutional investors (3/11) |
Encysive |
Private placement of convertible notes |
N/A |
$130 |
The 2.5% notes due 2012 initially are convertible into common stock at about $13.95 per share; the total includes the purchase of $15M in notes per an investor option (3/11) |
Evolutec |
Private placement of stock |
7.143S |
£9.5 (US$17.9) |
The shares were placed at 140 pence each in a deal fully underwritten by Collins Stewart; the shares were placed at a discount of 21.6% (3/23) |
Evotec OAI |
Private placement of stock |
10S |
€27.2 (US$36.6) |
Investors committed to purchase 10M share at €2.72 at the same time that Evotec disclosed its all-stock reacquisition of Evotec Neurosciences (3/7) |
GlycoGenesys |
Private sale of convertible stock and warrants |
2S and 2W |
$2 |
The company sold 2,000 shares of convertible, redeemable Series D preferred stock, currently convertible into 2M shares of common stock, and warrants to purchase 2M shares at $1.23 each; a second closing of $4.5M already has been agreed to (3/4) |
Helix |
Private placement of stock and warrants |
1.665S and 0.125W |
$2.5 |
Helix completed a two-part private financing that brought in a total of $2.5M; the five-year warrants are exercisable at $1.50 per share (3/2) |
Hemosol |
Private placement of convertible stock, stock and warrants |
N/A and 10.95S and 10.95W |
C$13.4 (US$11.1) |
Laurus Master Fund Ltd. purchased a three-year, 2%, $5M note convertible into stock at $0.69 per share; it also got a five-year warrant for the purchase of 2.73M shares at $0.86 and $1.04 per share; separately, Hemosol sold 10.95M special warrants at C$0.67 each; each consists of one share and a five-year warrant to purchase one share at C$1; Life Science Group Inc. and Loewen, Ondaatje, McCutcheon Ltd. were placement agents (3/31) |
Insmed Inc. |
Private placement of convertible notes and warrants |
N/A and 14.9W |
$35 |
The five-year, 5.5% notes are convertible into stock at $1.295 per share; the deal also included five-year warrants exercisable for 14.9M shares at an initial price of $1.36 per share; Wells Fargo Securities was lead placement agent; C.E. Unterberg, Towbin and Trout Capital LLC were co-agents (3/15) |
Life Medical |
Warrants exercise |
6.6S |
$0.8 |
The warrants, issued in a private placement in Europe in March 2003, were exercised at $0.12 each (3/31) |
Medical |
Private placement of securities |
ND |
$3 |
M.A.G. Capital LLC provided MDI with $3M for the acquisition of the German firm Savetherapeutics AG; financing terms were not disclosed (3/16) |
MorphoSys |
Private placement of stock |
0.49S |
€17.4 (US$23.1) |
Shares were sold at €35.50 each; WestLB AG was the sole manager for the deal (3/16) |
NeoRx Corp. |
Private placement of stock and warrants |
3.32S and 1.328W |
$4.1 |
The shares were sold at $1.25 each, and the five- year warrants are exercisable at $2 per share; Rodman & Renshaw LLC was placement agent (3/4) |
Neurologix |
Private placement of stock and warrants |
0.539S and 0.135W |
$0.7 |
The shares were sold at $1.30 each and the five- year warrants are exercisable at $1.625 per share; it was a follow-on deal to $2.46M in financings in January under the same terms (3/4) |
OxiGene Inc. |
Private placement of stock |
3.336S |
$15 |
The shares were sold from a shelf registration to institutional investors at $4.50 each; Legg Mason Wood Walker Inc. was lead placement, with Lazard Freres & Co. LLC co-placement agent (3/4) |
Plethora |
Stock sale |
7.4S |
£10 (US$18.7) |
The company, formerly named MedPharma plc, raised £10 as it gained a listing on the Alternative Investment Market, selling shares at 135 pence each and giving it a £30M market cap (3/24) |
Pluristem |
Private placement of stock and warrants |
ND |
$2.44 |
Pluristem completed a $3.2M interim financing; $0.76M of the total was disclosed in January; details on the financing were not disclosed (3/7) |
Point |
Private placement of stock |
3.65S |
$16.43 |
The shares were sold from a shelf registration at $4.50 each in a direct offering; SG Cowen & Co. LLC was lead agent and RBC Capital Markets was co- agent for the offering (3/1) |
Proximagen |
Private placement of stock |
9.12S |
£13.5 (US$25.4) |
Proximagen gained a listing on the AIM with the financing, and has a market capitalization of £29.7; KBC Peel Hunt Ltd. was adviser and broker in the deal (3/31) |
Sinovac |
Warrants exercise |
ND |
$3.4 |
Investors in a February 2004 financing exercised warrants at $1.70 per share; the company extended the exercise period until April 30 (3/1) |
VaxGen Inc. |
Private placement of convertible notes |
N/A |
$31.5 |
The 5.5% notes due 2010 initially are convertible into stock at $14.76 per share (3/31) |
V.I. |
Private placement of stock and warrants |
100S and 45W |
$20 |
The deal was made concurrent with the closing of the merger with Panacos Pharmaceuticals Inc.; the five-year warrants are exercisable at $0.24 per share; SG Cowen & Co. LLC was lead placement agent and Legg Mason Wood Walker was co-agent (2/11) |
Viventia |
Bridge loans |
N/A |
C$2 (US$1.64) |
Viventia Chairman Leslie Dan provided loans of C$0.5M and C$1.5M that carry a 4.5% annual interest rate; the board also authorized an additional bridge loan of C$42.6M from Dan (3/23) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange. | ||||
